Edition:
India

Shilpa Medicare Ltd (SHME.NS)

SHME.NS on National Stock Exchange of India

599.20INR
7 Aug 2020
Change (% chg)

-- (--)
Prev Close
Rs599.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,662
52-wk High
Rs618.40
52-wk Low
Rs208.10

Latest Key Developments (Source: Significant Developments)

Shilpa Medicare March Quarter Consol Profit Rises
Thursday, 18 Jun 2020 

June 18 (Reuters) - Shilpa Medicare Ltd ::MARCH QUARTER CONSOL NET PROFIT 345.7 MILLION RUPEES VERSUS 238.8 MILLION RUPEES.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 2.2 BILLION RUPEES VERSUS 2 BILLION RUPEES.  Full Article

India's Shilpa Medicare March-Qtr Consol Net Profit Rises
Monday, 15 Jun 2020 

June 15 (Reuters) - Shilpa Medicare Ltd ::MARCH-QUARTER CONSOL NET PROFIT 345.7 MILLION RUPEES VERSUS 238.8 MILLION RUPEES YEAR AGO.MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 2.20 BILLION RUPEES VERSUS 2 BILLION RUPEES YEAR AGO.  Full Article

Shilpa Medicare Launches Indian Branded Generic Of Anti-Cancer Drug Ibrutinib
Thursday, 28 May 2020 

May 28 (Reuters) - Shilpa Medicare Ltd ::LAUNCHES INDIAN BRANDED GENERIC OF ANTI-CANCER DRUG IBRUTINIB, WITH BRAND NAME IBRUSHIL.IBRUSHIL MONTHLY THERAPY COST WILL BE 34,920 RUPEES.  Full Article

Shilpa Medicare Gets UK MHRA Approval For Imatinib Oral Solution
Monday, 6 Apr 2020 

April 6 (Reuters) - Shilpa Medicare Ltd ::THROUGH UK UNIT KOANAA HEALTHCARE, GETS UK MHRA APPROVAL FOR IMATINIB ORAL SOLUTION.IMATINIB ORAL SOLUTION IS EXPECTED TO BE AVAILABLE IN THE UK IN Q2 OF 2020.IMATINIB ORAL SOLUTION EXPECTED TO HAVE PATENT PROTECTION UNTIL 2038.  Full Article

India's Shilpa Medicare Declares Interim Dividend At 1.10 Rupees/Share For FY 2019-20
Friday, 6 Mar 2020 

March 6 (Reuters) - Shilpa Medicare Ltd ::DECLARED INTERIM DIVIDEND AT 1.10 RUPEES/SHARE FOR FY 2019-20.  Full Article

India's Shilpa Medicare Reports Higher Dec-Quarter Profit
Monday, 10 Feb 2020 

Feb 10 (Reuters) - Shilpa Medicare Ltd ::DEC-QUARTER CONSOL NET PROFIT 550.6 MILLION RUPEES VERSUS 124.7 MILLION RUPEES YEAR AGO.DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 2.37 BILLION RUPEES VERSUS 1.73 BILLION RUPEES YEAR AGO.  Full Article

Shilpa Medicare Gets U.S FDA Tentative Approval For Its ANDA, Pirfenidone Tablets
Friday, 31 Jan 2020 

Jan 31 (Reuters) - Shilpa Medicare Ltd ::SHILPA MEDICARE LTD SAYS RECEIVED U.S FOOD AND DRUG ADMINISTRATION TENTATIVE APPROVAL FOR ITS ANDA, PIRFENIDONE TABLETS, 267 MG AND 801 MG.  Full Article

Shilpa Medicare Says Successful Closure Of Inspection, With Receipt Of EIR From FDA
Wednesday, 4 Dec 2019 

Dec 4 (Reuters) - Shilpa Medicare Ltd ::SHILPA MEDICARE -SUCCESSFUL CLOSURE OF INSPECTION, WITH RECEIPT OF EIR FROM FDA FOR INSPECTION AT SITE LOCATED AT RAICHUR, KARNATAKA.  Full Article

India's Shilpa Medicare Sept Quarter Consol Net Profit Rises
Monday, 11 Nov 2019 

Nov 11 (Reuters) - Shilpa Medicare Ltd ::SEPT QUARTER CONSOL NET PROFIT 507.8 MILLION RUPEES VERSUS 422.7 MILLION RUPEES YEAR AGO.SEPT QUARTER CONSOL REVENUE FROM OPERATIONS 2.90 BILLION RUPEES VERSUS 1.62 BILLION RUPEES YEAR AGO.  Full Article

Shilpa Medicare Gets USFDA Final Nod For Erlotinib Tablets
Wednesday, 6 Nov 2019 

Nov 6 (Reuters) - Shilpa Medicare Ltd ::GETS USFDA FINAL NOD FOR ITS ANDA, ERLOTINIB TABLETS, 25 MG, 100 MG, AND 150 MG.  Full Article

BRIEF-Shilpa Medicare March Quarter Consol Profit Rises

* MARCH QUARTER CONSOL NET PROFIT 345.7 MILLION RUPEES VERSUS 238.8 MILLION RUPEES